Silence Therapeutics plc
SLN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.50 | 0.00 | -0.04 |
| FCF Yield | -13.45% | -7.97% | -9.25% | -7.67% |
| EV / EBITDA | 0.06 | -10.32 | -2.42 | 28.32 |
| Quality | ||||
| ROIC | -15.09% | -15.93% | -17.10% | -0.99% |
| Gross Margin | 80.36% | 62.05% | 61.97% | 93.40% |
| Cash Conversion Ratio | 0.52 | 0.80 | 0.56 | -1.09 |
| Growth | ||||
| Revenue 3-Year CAGR | -3.94% | -3.35% | 4.22% | 33.64% |
| Free Cash Flow Growth | 50.35% | -77.31% | 50.59% | -26.47% |
| Safety | ||||
| Net Debt / EBITDA | 3.13 | 1.86 | 2.29 | -16.85 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.27 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -7,011.51 | -7,100.23 | -20,682.00 | -107.61 |